<code id='7DF7C751FB'></code><style id='7DF7C751FB'></style>
    • <acronym id='7DF7C751FB'></acronym>
      <center id='7DF7C751FB'><center id='7DF7C751FB'><tfoot id='7DF7C751FB'></tfoot></center><abbr id='7DF7C751FB'><dir id='7DF7C751FB'><tfoot id='7DF7C751FB'></tfoot><noframes id='7DF7C751FB'>

    • <optgroup id='7DF7C751FB'><strike id='7DF7C751FB'><sup id='7DF7C751FB'></sup></strike><code id='7DF7C751FB'></code></optgroup>
        1. <b id='7DF7C751FB'><label id='7DF7C751FB'><select id='7DF7C751FB'><dt id='7DF7C751FB'><span id='7DF7C751FB'></span></dt></select></label></b><u id='7DF7C751FB'></u>
          <i id='7DF7C751FB'><strike id='7DF7C751FB'><tt id='7DF7C751FB'><pre id='7DF7C751FB'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:explore    Page View:289
          A pair of scissor cuts four paper figures from a line of them — biotech coverage from STAT
          Adobe

          Sonata Therapeutics, a startup created two years ago through the merger of two Flagship Pioneering companies, has laid off about a third of its staff.

          The biotech laid off 21 employees in recent weeks, according to employee posts on social media and a company spokesperson. Sonata had around 63 employees before the layoffs.

          advertisement

          Sonata is just the latest in a series of startups laying off employees in order to stretch out their cash runways. Privately held startups have had a difficult time raising money during the recent biotech downturn, which has shown signs of abating in the last few months. But at this point, startups are still finding that private investors and venture capitalists are being cautious with their money as they wait to see if the downturn is truly over.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more
          Eli Lilly’s chief scientist on obesity drugs, gene editing, and more
          Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

          DanSkovronsky,EliLilly'schiefscientificofficer,atthe2023STATSummit.STATPHILADELPHIA—Inasense,theannu

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          A $475,000 price tag for a new cancer drug: crazy or meh?

          AlexHogan/STATForgetMcGregor-Mayweather.ThebiotechworldhasbeenwaitingformonthstohearaboutNovartis’s